{
    "nct_id": "NCT06428019",
    "official_title": "A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL",
    "inclusion_criteria": "* Diagnosis of documented, previously untreated, chronic lymphocytic leukemia (CLL) requiring treatment according to the 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria and have a life expectancy of > 6 months.\n* Previously untreated small lymphocytic lymphoma (SLL) meeting the 2018 iwCLL criteria for treatment will also be equally considered as CLL for eligibility, screening, treatment and evaluation.\n* Eastern Cooperative Oncology Group (ECOG) performance status <= 2.\n* Adequate marrow function independent of growth factor or transfusion support within 2 weeks of screening, unless cytopenia is due to marrow involvement of CLL as listed in the protocol.\n* Creatinine clearance (CrCl) >= 30 mL/min using the Cockcroft-Gault formula are eligible for inclusion.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "- Active/uncontrolled infection, no Richter's transformation, no active immune thrombocytopenia.",
    "miscellaneous_criteria": ""
}